Oncobiologics has signed an agreement with Parilis Biopharmaceuticals involving worldwide licensing for an undisclosed biotherapeutic product, and another agreement with a U.S.-based large pharmaceutical company to conduct research on solving issues related to downstream processing of monoclonal antibodies. The combined value of these agreements total approximately $80 million.   Dennis O’Donnell, chief executive officer of Parilis Biopharmaceuticals, said, “This is a major step for ...